ARPA‑H granted BioCurie up to $9.3 million to develop an AI‑powered digital platform for scalable gene therapy process development. BioCurie will integrate machine learning, modeling and real‑world manufacturing data alongside partners including Caring Cross, St. Jude Children’s Research Hospital and the Center for Breakthrough Medicines. CEO Irene Rombel framed the program as replacing trial‑and‑error process development with predictive simulation to shorten timelines and de‑risk production. The platform aims to serve both viral and non‑viral gene therapies and could alter cost and speed dynamics across advanced therapy manufacturing.